TransUnion FY2021 Form 10-K Summary
Business context and reporting period. This is TransUnion’s annual report for the fiscal year ended December 31, 2021, not a standalone quarterly filing. TransUnion provides credit information, analytics, identity and fraud solutions, marketing services, and consumer credit and identity-protection products. It reports three segments: U.S. Markets, International, and Consumer Interactive. All figures below are in U.S. dollars.
Financial performance and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $2,960.2 million | $2,530.6 million | +17.0% |
| Operating income | $647.7 million | $500.3 million | +29.5% |
| Income from continuing operations | $370.5 million | $305.7 million | +21.2% |
| Net income attributable to TransUnion | $1,387.1 million | $343.2 million | Includes large Healthcare sale gain in 2021 |
| Adjusted EBITDA (non-GAAP) | $1,156.9 million | $953.6 million | +21.3% |
| Adjusted EBITDA margin (non-GAAP) | 39.1% | 37.7% | +1.4 percentage points |
| Cash from continuing operating activities | $759.4 million | $716.3 million | +6.0% |
| Capital expenditures | $224.2 million | $205.6 million | +9.0% |
| Cash and cash equivalents at year-end | $1,842.4 million | $492.7 million | |
| Total debt at year-end | $6,365.9 million | $3,454.2 million |
FY2021 GAAP net income includes a $982.5 million after-tax gain on the sale of the Healthcare business. Continuing-operations diluted EPS was $1.84, compared with $1.53 in 2020; diluted EPS including discontinued operations was $7.19, compared with $1.79. Adjusted EBITDA is a non-GAAP measure and includes adjustments; it should not be treated as a substitute for GAAP profit or operating cash flow.
Segment revenue growth was broad-based: U.S. Markets revenue rose 18.6% to $1,791.0 million, International rose 20.5% to $701.9 million, and Consumer Interactive rose 6.4% to $545.8 million. International growth included a 4.5% benefit from stronger foreign currencies. U.S. Markets Adjusted EBITDA margin was 40.0%, International 42.8%, and Consumer Interactive 48.2%.
For the fourth quarter, revenue was $789.8 million, operating income was $114.0 million, and income from continuing operations was $34.4 million. Net income attributable to TransUnion was $1,017.4 million, substantially reflecting the Healthcare disposal gain recognized in the quarter.
Year-end total assets were $12,635.0 million and total stockholders’ equity was $4,006.2 million. The company had $299.9 million available under its $300 million revolving credit facility, with no revolver borrowings and $0.1 million of letters of credit outstanding. It reported compliance with debt covenants at year-end. The senior secured credit facility’s leverage test requires a ratio no higher than 5.5-to-1 at applicable measurement dates.
Material changes versus prior period
- Revenue and operating results improved as economic conditions recovered from the pandemic-related weakness of 2020; management cited stronger volumes, new product initiatives, acquisitions, and foreign-exchange benefits.
- Neustar and Sontiq were acquired on December 1, 2021, for cash purchase prices of $3,106.6 million and $642.8 million, respectively. Their results were included only from the acquisition date. The preliminary purchase-price allocation included $2,346.0 million of goodwill in total.
- The Healthcare business was sold on December 17, 2021, for $1,705.9 million cash, subject to a final working-capital adjustment. The sale generated a $982.5 million after-tax gain and is presented as discontinued operations.
- Debt increased primarily to finance Neustar. TransUnion borrowed $3.1 billion under its senior secured facility and initially borrowed $640 million under a second-lien loan to finance Sontiq; the latter was repaid in December using Healthcare-sale proceeds. In January 2022, the company prepaid another $400 million of senior secured term loans.
- Operating expenses increased 13.9% to $2,312.5 million, reflecting higher revenue-related costs, acquisition and integration expenses, labor and technology investment. Adjusted EBITDA growth also benefited from lower legal and regulatory costs and reversals of pandemic-era bad-debt reserves.
Outlook, commentary, risks, and unusual items
- Outlook: The filing does not provide a clear numerical FY2022 revenue or earnings guidance range. Management expected global growth to remain strong but slow, while highlighting inflation, geopolitical tensions, COVID-19 variants, consumer-confidence concerns, interest-rate pressure, supply constraints, and labor shortages. It expected mortgage business declines to continue as interest rates rise.
- Liquidity uses: Management said cash, operating cash flow, and revolver availability should fund planned needs for the foreseeable future. It expected to pay approximately $352 million of taxes related to the Healthcare sale in April 2022 and planned to fund a $515 million Verisk Financial Services acquisition from cash on hand, subject to closing conditions and regulatory approvals.
- CFPB matter: The CFPB’s Enforcement Division obtained authority to pursue an action alleging failure to comply with a 2017 consent order and other Consumer Interactive marketing violations. The company was in settlement discussions, had accrued $26.5 million, and disclosed a reasonable possibility of a loss above that accrual; any excess range was not reasonably estimable.
- Ramirez litigation: In January 2022, TransUnion reached a tentative class settlement, subject to court approval, and expected resolution by year-end 2022. The filing reports that the estimate of the probable loss and related insurance receivable was revised in 2021.
- Other risks: Key exposures include cybersecurity and data privacy, regulatory change and litigation, customer and data-provider concentration, competition and pricing, pandemic effects, acquisition integration, foreign-exchange movements, and substantial variable-rate debt. Interest-rate swaps hedge portions of the exposure; essentially all outstanding debt was variable-rate before considering those hedges.
- Other unusual items: The company recorded $48.1 million in acquisition fees, $9.1 million in Neustar integration costs, and $42.3 million in accelerated technology investment expenses during 2021. These are among the items excluded from Adjusted EBITDA. The acquisitions’ purchase-price allocations were preliminary at year-end.
Important facts for investors to verify
- Separate recurring continuing-operations performance from the $982.5 million after-tax Healthcare disposal gain when assessing 2021 net income and EPS.
- Review the final acquisition accounting, integration costs, and realized revenue or cost synergies for Neustar and Sontiq.
- Track resolution and any additional exposure in the CFPB matter and Ramirez settlement, including amounts beyond recorded accruals.
- Assess debt levels, post-year-end repayments, interest-rate hedges, covenant headroom, and planned cash uses for taxes and the announced acquisition.
- Compare reported growth with acquisition and foreign-currency contributions, and monitor mortgage volumes, macroeconomic conditions, and pandemic-related demand.